- Display 15 Products per page
Published: June 13, 2013 | Price: $2,500.00 – $5,000.00
In recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases. This comprehensive report, The World Market for Orphan Drugs, looks at this trend and provides estimates for the market opportunity in the U.S., Europe, Japan and globally. With over 400 pages of market analysis and over 120 figures and tables, the report provides in-depth coverage of key competitors and important trends and challenges for makers of orphan drug treatments. Osteoporosis,...Published: May 7, 2012 | Price: $3,995.00 – $7,990.00
Over-the-counter (OTC), non-legend, and non-prescription are all adjectives describing drugs that an individual may purchase without a prescription. Many pharmaceutical companies seeking more revenue and international exposure have found an opportunity in the development of over-the-counter (OTC) drugs. OTC drugs are sold to consumers by convenience and grocery stores. However, new technology has allowed a new range of outlets including online sales and catalog. Drugs included in OTC segments are pain relievers, cough and cold remedies, sleeping aids, antifungals, and...Published: February 1, 2012 | Price: $3,800.00 – $7,600.00
This Kalorama Information report – The World Market for Anti-Infectives - focuses on three key segments of treatment: Antifungals (Allylamines, Azoles, Polyene Macrolides, Other Antifungals) Antibacterials (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others) Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) The report covers both currently marketed and late stage development products. Revenues for each segment were generated using dollar and unit sales for each product. A novel approach in this report is that...Published: February 1, 2012 | Price: $2,500.00 – $5,000.00
Vaccines are among the top revenue earners in recent years, and in some cases have assisted major pharmaceutical companies to revenue growth. But this is not without some trade-offs. Vaccines involve a complex production process. Is vaccine-making profitable? How much is the industry spending? How much is handed off to other companies and how much is made by the branded manufacturers? How many doses are produced by the industry? These are the type of questions that Kalorama Information has taken...Published: December 1, 2011 | Price: $150.00 – $300.00
Kalorama Information reports on a wide range of topics related to healthcare industry markets in the United States. This report, The Kalorama U.S.Pharmaceutical, Medical Device, Diagnostics Markets provides a broad look at the healthcare system and a summary of the market for the healthcare industry in the United States. The report discusses a range of topics impacting the industry: Healthcare Reform - What Impact Will Be Had on Each Healthcare Industry? How Will Physicians, Patients, Payors, and the Uninsured Be...Published: February 1, 2011 | Price: $150.00 – $300.00
While many areas of the pharmaceutical industry will suffer from current economic conditions worldwide, sales of over-the-counter drugs are widely anticipated to grow as consumers seek cheaper alternatives. Manufacturers are expected to switch prescription drugs to over-the-counter status where possible. In the early part of the last decade there was a decline in Rx-to-OTC switches; since 2006, however, there has been a number of uses of this tactic to extend the revenue of pharmaceutical products. In Kalorama Information's Market for...Published: May 1, 2010 | Price: $3,995.00 – $7,990.00
Over-the-Counter (OTC) drugs are non-prescription drugs sold to consumers at pharmacies, convenience and grocery stores. These drugs include pain relievers, cough and cold remedies, sleeping aids, antifungals, and other products approved for use as a self-medication product. There has been a particular focus in the pharmaceutical industry on OTC drugs, and in several market research reports over the past decade, Kalorama Information has covered the strategies pharmaceutical companies are using in the OTC market. This report, The Worldwide Over the...Published: April 1, 2010 | Price: $3,995.00 – $7,990.00
This Kalorama Information report - The World Anesthesia Drug Market - focuses on three primary segments of anesthesia: General Anesthesia Local Anesthesia Adjunctive Therapies in Anesthesia The report covers both currently marketed and late stage development anesthesia drugs in detail. Revenues for each segment were generated using dollar and unit sales for each product. Forecasted figures were generated using a combination of projected surgical procedures, patent and exclusivity expirations, pricing trends, new developments and other factors. The report includes statistical...Published: May 1, 2009 | Price: $995.00 – $7,000.00
While many areas of the pharmaceutical industry will suffer from current economic conditions worldwide, sales of over the counter drugs are widely anticipated to grow as consumers seek cheaper alternatives. Manufacturers are expected to switch prescription drugs to over the counter status where possible. In the early part of this decade there was a delcine in Rx to switches, since 2006 there has been a number of uses of this tactic to extend revenue of pharmaceutical products. In Kalorama Information's...Published: January 1, 2009 | Price: $995.00 – $7,000.00
This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing of prescription drugs and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. A major factor driving the upward trend in the number of manufacturing projects being outsourced is that specialized production, i.e., sterile manufacturing, biopharmaceutical manufacturing and specialized processes, such as chiral chemistry and improvements in catalyst activity, is often not included in the...Published: May 1, 2008 | Price: $995.00 – $6,400.00
Over-the-counter (OTC) drugs are well situated to capitalize on worldwide economic conditions. Customers in the US and in the world under time constraints and tight budgets prefer OTC and are opting to self-medicate where possible. Developing and petro-rich nations are pushing world demand for pharmaceuticals. Pharmacists are favoring OTCs, and are a driving force behind a new class of 'behind the counter' (BTC) drugs. The aging of the population and an increase in medical conditions generally continues to bode well...Published: April 1, 2008 | Price: $500.00 – $3,990.00
Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and Kalorama Information believes this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue life. Kalorama Information's The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contians a complete overview of the US market for prescription drugs likely to switch in the...Published: March 1, 2008 | Price: $995.00 – $3,990.00
Pharmaceutical manufacturers are utilizing new RIFD technologies to deal with multiple challenges they face in the manufacturing process. This Kalorama Information report discussions the solutions available, and covers the opportunities available to technology companies to provide services to this sector. Full coverage of the market for RFID technologies in pharmaceutical manufacturing operations is provided, including. Explanation of RFID Technologies Cost Savings from Implementation Total Market for RFID Technologies in Pharma Manufacturing Market Forecasts Major Companies Involved in RFID and...Published: September 1, 2006 | Price: $3,900.00 – $7,800.00
This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. The report contains vital market statistics on three main segments of pharmaceutical contract manufacturing: Biopharmaceutical manufacturing, including monoclonal antibodies (MAbs), complex proteins, peptides, nucleotides, DNA vaccines, and gene therapy. Primary pharmaceutical manufacturing, including non-sterile and sterile active pharmaceutical ingredients (APIs), custom chemicals, certain specialized manufacturing...Published: January 1, 2006 | Price: $995.00 – $5,990.00
With the mapping of the human genome and the concomitant explosion of proteomics, a steady stream of biopharmaceuticals have been launched—recombinant therapeutic proteins, monoclonal antibody-based products used for therapeutic or in vivo diagnostic purposes, and nucleic acid-based products. As the rate of regulatory approval for biopharmaceuticals increases, the number of products reaching the market will impose unprecedented demands on the industry’s biomanufacturing capacity. Whether or not this will create a biomanufacturing bottleneck is a hotly debated issue in the industry....